Navigation Links
KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
Date:11/1/2013

NORTH LIBERTY, Iowa, Nov. 1, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201 (benzhydrocodone hydrochloride and acetaminophen).  Based on the results of the meeting, KemPharm believes the completed and ongoing clinical, non-clinical and CMC development programs will allow for the submission of a New Drug Application (NDA) for KP201 in the third quarter of 2014.

During the meeting, representatives from the FDA reviewed KemPharm's current portfolio of data for KP201, including the recently completed bioequivalence and "steady-state" pivotal clinical studies.  It was determined that the final data package, as proposed by KemPharm, would support a potential 505(b)(2) filing pathway without any additional efficacy, toxicology or safety data being required.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "The positive feedback we received from the Agency re-affirms prior discussions related to our clinical and non-clinical program for KP201 and our plan to pursue an NDA via the 505(b)(2) pathway. Based on their advice, we are extremely confident in our plan to submit an NDA by the third quarter of 2014 and seek potential approval of the first novel pain therapy of the morphine class to be developed in a number of years with an officially recognized new chemical structure."

KP201 is in development for the treatment of acute moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induce
'/>"/>

SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
2. KemPharms KP201 Featured at the International Conference on Opioids
3. Micropharma completes development of first microbiome clinical lab test using digital PCR technology
4. Syneron Medical Completes and Summarizes the Multi-site Clinical Study Agreed Upon with FDA for the UltraShape Contour I
5. AIS (American Internet Services) Completes Audit for Title 21 CFR Part 11 Compliance
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
8. Boston Scientific Completes $1.05 Billion Senior Notes Offering
9. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
10. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
11. Oligomerix, Inc. Completes Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to ... Tech , an e-Journal and producer of Food ... second year for the co-location of Food Labs Conference to ... that the registration fee to attend the two-day Food Lab ...
(Date:1/15/2014)... 15, 2014 Look inside the new ... for the lab, from fluid handling to instruments to ... ship when you order. , Preferred Solutions features ... from the L/S® model for precise flow control and ...
(Date:1/15/2014)... and SAN JOSE, California , ... biotechnology company developing antibody-drug conjugates for cancer, today announced the ... of Directors. Dr Reynolds has over 20 years, development experience ... Officer at Seattle Genetics. "I am delighted to ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... Mylan Inc. (Nasdaq: MYL ) today ... company,s credit ratings, including the "Corporate Family Rating," to ... is stable.  According to Moody,s: "Mylan,s ... in the global generic pharmaceutical industry, its strong geographic ...
... a molecular diagnostics company, announced today the publication of ... which may influence the amount of fetal DNA found ... Kypros Nicolaides, MD, of Harris Birthright Research Centre for ... Kingdom. (Logo: http://photos.prnewswire.com/prnh/20120326/NY75864LOGO ) ...
... a metal surface at the scale of atoms and ... computer chips or the reflective silver in optical components ... may seem high-tech and precise, the technique has been ... physics. In a new study, Brown University engineers modeled ...
Cached Biology Technology:Moody's Upgrades Mylan 2Ariosa Diagnostics Announces Publication of Study on Influential Factors Affecting Fetal DNA Concentration in Blood of Pregnant Women 2How ion bombardment reshapes metal surfaces 2How ion bombardment reshapes metal surfaces 3
(Date:4/17/2014)... modeling study suggests that fish consumption advisories for ... to long-lived contaminants like persistent organic pollutants (POPs). ... of researchers including University of Toronto Scarborough PhD ... at how different levels of environmental contamination, a ... chemicals in the body influenced exposure in her ...
(Date:4/17/2014)... in German . ... they also provide us with a continuous stream of information ... or sit still in a car the world glides ... retinas. Seemingly without effort, our brain calculates self-motion from this ... and a steady gaze during our own movements. Together with ...
(Date:4/17/2014)... professor Rajendra Singh Thursday as a "Champion of ... solar deployment in the residential, commercial and industrial ... of Electrical and Computer Engineering and director of ... local hero leading the charge across the country ... power and driving policy changes at the local ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... applauds the US Court of Appeals for the District of ... against the use of public funds for embryonic stem cell ... cell research and the nation,s scientific community. Most importantly, ... suffering from incurable diseases," says Susan L. Solomon, CEO of ...
... a groundbreaking new videojournal to complement the ... & Advanced Surgical Techniques has been ... ( http://www.liebertpub.com ). Videoscopy ( http://www.liebertpub.com/products/product.aspx?pid=390 ) ... of the latest techniques and technologies used ...
... ground to plant trees may be an excellent gateway to ... University of Maryland study, based on work with New York ... in environmental stewardship, the more s/he engages with other types ... Together ", which the researchers released to coincide with Arbor ...
Cached Biology News:Groundbreaking minimally invasive surgical videojournal launched by Mary Ann Liebert Inc. 2Digging in dirt, Arbor Day planting, may help build citizenship: UMD study 2
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Anti-human C5/C5b, Clone 568, Monoclonal Antibody...
Biology Products: